title: Sertraline in the treatment of major depression following mild traumatic brain injury.
abstract: An 8-week, nonrandomized, single-blind, placebo run-in trial of sertraline was conducted on 15 patients diagnosed with major depression between 3 and 24 months after a mild traumatic brain injury. On the Hamilton Rating Scale for Depression, 13 (87%) had a decrease in score of > or = 50% ("response"), and 10 (67%) achieved a score of < or = 7 ("remission") by week 8 of sertraline. There was statistically significant improvement in psychological distress, anger and aggression, functioning, and postconcussive symptoms with treatment.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Fann
authors.forename: J M
authors.initials: JM
authors.lastname: Uomoto
authors.forename: W J
authors.initials: WJ
authors.lastname: Katon
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001924:Brain Concussion / Q000150:complications* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D018434:Sickness Impact Profile
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline